Week in Review: Otsuka Pays $78 Million for Asian Rights to Ariad's Leukemia Drug

Otsuka Pharma of Japan paid $77.5 million upfront for rights to market an Ariad Pharma leukemia drug in Japan, China and eight other Asian countries; Therapix Biosciences, an Israeli biotech accelerator, announced an MOU to out-license China rights for its anti-CD3 antibody to Nanjing BioSciKin; Eddingpharm of China secured greater China rights to Brinavess™, a treatment for Afib, from Cardiome Pharma of Canada; China Pioneer Pharma expanded its relationship with Swiss pharma Polichem SA to include a treatment for Parkinson's disease; China is expected to change the way it sets drug prices, ending the preferential pricing for mature off-patent drugs made by multinational pharmas; and China also agreed to speed up approvals of US drugs and medical devices at a bi-lateral meeting of US-China trade officials. More details.... Stock Symbols: (TYO: 4768) (NSDQ: ARIA) (TASE: TRPX; OTCQB: THXBY) (NSDQ: CRME; TSX: COM) (HK: 1345) Share this with colleagues: // //